Opendata, web and dolomites

EuroXpand SIGNED

EUROpean clinical validation of a new ex vivo eXpanded stem cell theraPy for cArdiac regeNeration after acute myocarDial infarction: EUROXPAND

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 EuroXpand project word cloud

Explore the words cloud of the EuroXpand project. It provides you a very rough idea of what is the project "EuroXpand" about.

2008    prevent    35    total    unlike    affordable    global    prevention    creation    successful    assets    combined    pr    patented    hence    founder    function    safety    infarction    cardiac    euroxpand    excellent    operative    model    centres    reg    demonstration    indicated    kit    discoveries    health    expansion    efficacy    billion    socio    pilot    treatments    reference    83    characterised    stemxpand    surgical    profile    jobs    demonstrated    stempack    heart    therapy    millions    indirect    decreasing    burdensome    cellprothera    recovery    business    position    nor    eacute    invasive    ami    2021    clinical    turnover    euros    context    first    outstanding    direct    fail    treatment    post    least    death    leader    stem    limiting    acute    proof    thanks    industrialised    outcomes    expectancy    innovative    professional    competitors    2022    possession    countries    cancer    public    automate    75    reinsertion    founded    thousands    myocardial    patients    cells    worked    issue    worldwide    hf    life    cell   

Project "EuroXpand" data sheet

The following table provides information about the project.

Coordinator
CELLPROTHERA 

Organization address
address: 12 RUE DU PARC
city: MULHOUSE
postcode: 68100
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 5˙000˙000 €
 EC max contribution 5˙000˙000 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-2-2016-2017
 Funding Scheme SME-2
 Starting year 2018
 Duration (year-month-day) from 2018-05-01   to  2021-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CELLPROTHERA FR (MULHOUSE) coordinator 5˙000˙000.00

Map

 Project objective

Heart failure (HF) after acute myocardial infarction (AMI) remains the first cause of death in developed countries, above cancer, with a life expectancy less than 5 years. With an overall cost of 83 billion euros per year worldwide , HF represents a global public-health issue. Treatments following AMI are still characterised by burdensome surgical procedures and post-operative treatments which both fail to prevent HF development. In this context, CellProthera, founded in 2008, developed an innovative technology based on the discoveries of its founder, Pr. Hénon, who has worked on stem cells for more than 35 years. Unlike its competitors, CellProthera has already demonstrated the efficacy and the safety of its cell therapy, thanks to a successful Proof of Concept study. The clinical outcomes indicated an excellent safety profile associated with an outstanding long-term recovery of the cardiac function, facilitating socio-professional reinsertion. The process used during the pilot phase could not be patented nor industrialised, limiting its availability to all patients. Hence, Cellprothera has developed a patented cell expansion automate StemXpand®, combined with StemPack® Kit creating an innovative business model, and a new cell therapy process less invasive, more affordable, and decreasing health costs related to HF in the order of 50 to 75%. With the efficacy demonstration of the new process through EuroXpand project, Cellprothera’s cell therapy could become the reference treatment to prevent HF after AMI. This way, CellProthera will be in possession of all the assets required to achieve a leader position in HF prevention, after AMI. Indeed, with a potential of millions patients / year worldwide, Cellprothera’s total turnover is expected to reach 1,9 billion euros in 2021, associated to the creation of at least 40 direct jobs by 2022 and several thousands of indirect jobs, particularly in Cell Therapy Centres.

 Deliverables

List of deliverables.
Communication material (brochures, web…) Documents, reports 2020-02-12 17:33:26
Press Release - Project kick-off Documents, reports 2020-02-12 17:33:28

Take a look to the deliverables list in detail:  detailed list of EuroXpand deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EUROXPAND" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EUROXPAND" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

ESCALON (2019)

European-Latin American network for the assessment of biomarkers to predict and diagnose hepatobiliary malignancies and characterization of risk factors for cancer development

Read More  

PREFERABLE (2019)

Project on Exercise for Fatigue Eradication in Advanced Breast cancer to improve quality of life

Read More  

CLOSER (2019)

Childhood Leukemia: Overcoming distance between South America and Europe Regions

Read More